Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Florastamin (18F) PET/CT for Localisation of Clinically Significant Prostate Cancer in Patients with Negative or Low-Suspicion mpMRI
2023-510421-14-00Phase 3Completed
- Sponsor
- Curium
- Start
- Aug 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fluciclovine f 18 in prostate cancer (PCa), sponsored by Curium. Primary endpoint: Localisation of clinically significant prostate cancer in patients with elevated PSA and/or PSA density and clinical suspicion of prostate cancer. Started Aug 2024; status: completed.
02
Drugs
fluciclovine f 18
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2023-510421-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510421-14-00.